Payment overview · 2025
General Payments
$16.95
1 reported records · 1 companies
Healthcare provider profile · identity verified
Sandra Y Goldring, MD
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTA, GA · NPI 1922411636
Verified facts
What the public records show
CMS Open Payments records show Sandra Y Goldring, MD received $16.95 in general payments during 2025 across 1 reported records.
GlaxoSmithKline, LLC. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Trelegy Ellipta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $16.95 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $16.95 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $16.95 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
47 | 11 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Amlodipine Besylate | Amlodipine Besylate | 1315 | 489 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1165 | 445 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 620 | 225 |
| Lisinopril | Lisinopril | 597 | 219 |
| Gabapentin | Gabapentin | 578 | 210 |
| Ozempic | Semaglutide | 560 | 119 |
| Losartan Potassium | Losartan Potassium | 552 | 207 |
| Hydrochlorothiazide | Hydrochlorothiazide | 466 | 179 |
| Fluticasone Propionate | Fluticasone Propionate | 457 | 204 |
| Omeprazole | Omeprazole | 448 | 157 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 416 | 160 |
| Metoprolol Succinate | Metoprolol Succinate | 406 | 145 |
| Trulicity | Dulaglutide | 310 | 78 |
| Diclofenac Sodium | Diclofenac Sodium | 307 | 111 |
| Furosemide | Furosemide | 281 | 119 |
| Metformin Hcl | Metformin Hcl | 276 | 112 |
| Carvedilol | Carvedilol | 267 | 107 |
| Levothyroxine Sodium | Levothyroxine Sodium | 252 | 77 |
| Farxiga | Dapagliflozin Propanediol | 236 | 80 |
| Spironolactone | Spironolactone | 210 | 79 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 78 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 198 | 89 |
| Tizanidine Hcl | Tizanidine Hcl | 194 | 89 |
| Ventolin Hfa | Albuterol Sulfate | 188 | 67 |
| Allopurinol | Allopurinol | 181 | 66 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 176 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 175 | 71 |
| Ibuprofen | Ibuprofen | 174 | 64 |
| Januvia | Sitagliptin Phosphate | 173 | 59 |
| Tresiba Flextouch U-100 | Insulin Degludec | 173 | 60 |
| Pantoprazole Sodium | Pantoprazole Sodium | 163 | 68 |
| Potassium Chloride | Potassium Chloride | 162 | 51 |
| Famotidine | Famotidine | 159 | 57 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 156 | 51 |
| Montelukast Sodium | Montelukast Sodium | 151 | 65 |
| Pregabalin | Pregabalin | 131 | 37 |
| Simvastatin | Simvastatin | 123 | 45 |
| Eliquis | Apixaban | 119 | 35 |
| Duloxetine Hcl | Duloxetine Hcl | 116 | 44 |
| Naproxen | Naproxen | 116 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 115 | 41 |
| Colchicine | Colchicine | 114 | 36 |
| Trazodone Hcl | Trazodone Hcl | 112 | 42 |
| Meloxicam | Meloxicam | 108 | 45 |
| Glipizide Er | Glipizide | 107 | 34 |
| Hydralazine Hcl | Hydralazine Hcl | 107 | 48 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 107 | 54 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 105 | 40 |
| Chlorthalidone | Chlorthalidone | 104 | 41 |
| Metformin Hcl Er | Metformin Hcl | 104 | 46 |
| Mirtazapine | Mirtazapine | 104 | 37 |
| Symbicort | Budesonide/Formoterol Fumarate | 102 | 35 |
| Meclizine Hcl | Meclizine Hcl | 97 | 22 |
| Baclofen | Baclofen | 96 | 35 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 93 | 34 |
| Nifedipine Er | Nifedipine | 91 | 39 |
| Lidocaine | Lidocaine | 90 | 34 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 90 | 35 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 89 | 29 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 29 |
| Sertraline Hcl | Sertraline Hcl | 88 | 33 |
| Prednisone | Prednisone | 84 | 76 |
| Ezetimibe | Ezetimibe | 82 | 30 |
| Alendronate Sodium | Alendronate Sodium | 81 | 29 |
| Lactulose | Lactulose | 81 | 32 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 81 | 36 |
| Clopidogrel | Clopidogrel Bisulfate | 72 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 68 | 29 |
| Finasteride | Finasteride | 61 | 23 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 60 | 21 |
| Jardiance | Empagliflozin | 57 | 25 |
| Azelastine Hcl | Azelastine Hcl | 54 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 53 | 16 |
| Torsemide | Torsemide | 52 | 17 |
| Tramadol Hcl | Tramadol Hcl | 52 | 23 |
| Atenolol | Atenolol | 51 | 17 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 50 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 50 | 20 |
| Oxybutynin Chloride | Oxybutynin Chloride | 49 | 15 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 48 | 19 |
| Novolog Flexpen | Insulin Aspart | 48 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 47 | 11 |
| Spiriva Respimat | Tiotropium Bromide | 46 | 16 |
| Citalopram Hbr | Citalopram Hydrobromide | 45 | 14 |
| Ketoconazole | Ketoconazole | 45 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 45 | 23 |
| Clonidine Hcl | Clonidine Hcl | 44 | 12 |
| Fluconazole | Fluconazole | 44 | 31 |
| Techlite Pen Needle | Pen Needle, Diabetic | 42 | 31 |
| Valsartan | Valsartan | 42 | 15 |
| Levetiracetam | Levetiracetam | 39 | 18 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 38 | 11 |
| Levemir Flexpen | Insulin Detemir | 38 | 22 |
| Bupropion Hcl Sr | Bupropion Hcl | 37 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 37 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | 15 |
| Lorazepam | Lorazepam | 35 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 35 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 34 | 14 |
| Clindamycin Phosphate | Clindamycin Phosphate | 34 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 34 | 15 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 17 |
| Droplet Pen Needle | Pen Needle, Diabetic | 32 | 12 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Bupropion Xl | Bupropion Hcl | 30 | 11 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 30 | 12 |
| Tresiba | Insulin Degludec | 30 | 11 |
| Amitriptyline Hcl | Amitriptyline Hcl | 29 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 29 | suppressed |
| Hydrocortisone | Hydrocortisone | 29 | 14 |
| Levemir | Insulin Detemir | 29 | 11 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 29 | 13 |
| Estradiol | Estradiol | 28 | suppressed |
| Glimepiride | Glimepiride | 28 | 12 |
| Incruse Ellipta | Umeclidinium Bromide | 28 | suppressed |
| Azithromycin | Azithromycin | 27 | 25 |
| Ondansetron Odt | Ondansetron | 27 | 23 |
| Xarelto | Rivaroxaban | 27 | 13 |
| Ipratropium Bromide | Ipratropium Bromide | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | 12 |
| Atrovent Hfa | Ipratropium Bromide | 25 | suppressed |
| Methimazole | Methimazole | 25 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Premarin | Estrogens, Conjugated | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 24 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 23 | suppressed |
| Verapamil Er | Verapamil Hcl | 23 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 22 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 21 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 20 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 20 | 11 |
| Topiramate | Topiramate | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Novolog | Insulin Aspart | 19 | suppressed |
| Trueplus Insulin Syringe | Syringe And Needle,insulin,1ml | 19 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Clonidine | Clonidine | 18 | suppressed |
| Ibu | Ibuprofen | 18 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 17 | 15 |
| Latanoprost | Latanoprost | 17 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Aripiprazole | Aripiprazole | 16 | suppressed |
| Linzess | Linaclotide | 16 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 16 | 12 |
| Victoza 3-Pak | Liraglutide | 16 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 15 | 13 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Methocarbamol | Methocarbamol | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 14 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 14 | 13 |
| Victoza 2-Pak | Liraglutide | 14 | suppressed |
| Acyclovir | Acyclovir | 13 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Novolin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 13 | suppressed |
| Amoxicillin | Amoxicillin | 12 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 12 | suppressed |
| Insupen Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Klor-Con M15 | Potassium Chloride | 12 | suppressed |
| Loperamide | Loperamide Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Klor-Con M10 | Potassium Chloride | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Penicillin V Potassium | Penicillin V Potassium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $16.95 · 1 records | GlaxoSmithKline, LLC. | BEXSERO, SHINGRIX | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error